I-131 Therapy for Hyperthyroidism: Dosimetry

Radioiodine (I-131) is a definitive, decades-proven therapy for hyperthyroidism—and choosing the administered activity is as much a physics decision as a clinical one. The therapeutic dose is delivered almost entirely by short-range beta particles that the thyroid concentrates from orally administered sodium iodide, so the outcome hinges on how much iodine the gland traps, how long it retains it, and how large the gland is. This article compares fixed and calculated dosing, works through the uptake-corrected concentration formula and the absorbed-dose approach, and ties the calculation to the NRC written-directive and patient-release framework.¹²³

Introduction

Hyperthyroidism—most commonly from Graves disease, toxic multinodular goiter, or a toxic autonomous nodule—can be treated with antithyroid drugs, surgery, or radioiodine. Radioiodine therapy is attractive because it is outpatient, avoids surgical risk, and is highly effective, but it requires a deliberate activity-selection decision that determines both efficacy (cure of hyperthyroidism) and the trade-off with post-treatment hypothyroidism.²

That decision is where the medical physicist and the authorized user meet. The physics is governed by iodine biokinetics: fractional uptake, effective half-life, and gland mass. The clinical goal—non-ablative control versus deliberate ablation—sets the target. And the regulatory framework—written directive, authorized-user training, and patient release—wraps the whole process. Understanding all three is what separates a defensible radioiodine program from one that simply administers a habitual number of millicuries.¹²³

DRPS supports nuclear medicine and radioiodine therapy programs as part of PET/CT and nuclear medicine physics and radiation safety officer consulting across Florida, Maryland, Virginia, Washington DC, California, Nevada, and our other service areas.

Topic Explanation

Why iodine-131 works for the thyroid

The thyroid is uniquely avid for iodine, and I-131 exploits that physiology. Sodium iodide I-131 is trapped and organified by functioning thyroid tissue, concentrating the radionuclide precisely where the therapeutic effect is needed. I-131 decays with a physical half-life of about 8.02 days, emitting beta particles with a maximum energy of about 606 keV (mean energy roughly 192 keV) and a principal gamma photon at 364 keV (about 81.5% abundance).⁹

The therapeutic work is done by the beta particles, which have a short range in tissue (on the order of a couple of millimeters) and therefore deposit their energy locally within the gland while largely sparing surrounding structures. The 364 keV gamma is not the therapeutic agent—it is why the patient becomes an external radiation source and why patient-release and shielding considerations exist. For a refresher on the measurement that feeds dosing, see thyroid uptake measurement; for the internal-dose framework, see the MIRD schema for internal dosimetry.

The three biokinetic inputs

Every activity-selection method depends on some combination of three quantities:

Gland mass ( $m$ ) — estimated by palpation, but far better by ultrasound (or scintigraphy). Mass scales the amount of tissue that must be irradiated.
Fractional radioiodine uptake ( $f$ ) — the fraction of administered iodine the gland traps, most often measured at 24 hours (RAIU). Only the trapped fraction contributes therapeutic dose.
Effective half-life ( $T_{eff}$ ) — the combination of physical decay and biological clearance that determines how long the trapped iodine keeps irradiating the gland. It varies between patients; a standard value (often around 5–6 days) is sometimes assumed when patient-specific measurement is impractical.⁶

Key Technical Principles

Fixed versus calculated activity

There is a long-running, legitimate debate between two philosophies.²⁵⁶

Fixed (empiric) activity administers a standard activity chosen by diagnosis and gland size. It is simple and reproducible and does not require an uptake measurement at the time of dosing.
Calculated (individualized) activity adjusts the administered activity for gland mass and 24-hour uptake, and in fuller forms for effective half-life. It tailors dose to the patient and can lower the average administered activity while maintaining efficacy.⁶

Modeling and prospective comparisons show that elaborate dosimetry does not always beat a well-chosen standard activity for cure rate, but individualized methods can reduce administered activity and, when the target absorbed dose is set high enough, achieve high cure rates.⁵⁶⁷ The following table summarizes representative approaches; specific activities must be set by the authorized user for the individual patient.

Approach	What it uses	Representative administered activity	Practical notes
Fixed — Graves disease	Diagnosis, rough gland size	≈ 370–555 MBq (10–15 mCi)	Simple, reproducible; no same-day uptake needed ²
Fixed — toxic multinodular goiter	Diagnosis, gland size	Often higher, ≈ 555–1110 MBq (15–30 mCi)	Nodular tissue is more radioresistant ¹²
Calculated — concentration method	Target µCi/g, mass, 24-h uptake	Derived (see worked example)	Lowers average activity; needs accurate mass + uptake ²⁶
Full dosimetry — absorbed dose	Target Gy, mass, uptake, $T_{eff}$	Derived	Most individualized; needs effective half-life ³⁷

Historical cohort reconstruction of a very large hyperthyroid population found mean administered activities of about 380 MBq for Graves disease and about 640 MBq for toxic nodular goiter—consistent with the ranges above.⁴

The concentration (uptake-corrected) formula

The most widely used practical calculation targets a radioiodine concentration in the gland and corrects for uptake. If the target concentration is $C$ (activity per gram), the gland mass is $m$ , and the fractional 24-hour uptake is $f$ , the administered activity $A$ is:

A = \frac{C \cdot m}{f}

The logic is direct: to deposit $C \cdot m$ of activity in the gland, and only a fraction $f$ of what you give is trapped, you must administer $C \cdot m / f$ .

Worked example. Target concentration $C = 160 μ Ci/g$ (a representative value used in calculated Graves dosing), gland mass $m = 40$ g, and measured 24-hour uptake $f = 0.60$ :²

A = \frac{160 μ Ci/g \times 40 g}{0.60} = \frac{6400}{0.60} \approx 10, 670 μ Ci \approx 10.7 mCi \approx 395 MBq

If the same gland had a lower uptake of $f = 0.40$ , the required activity would rise to about 16 mCi (≈ 590 MBq); a higher uptake of $f = 0.80$ would lower it to about 8 mCi (≈ 296 MBq). This is exactly why the uptake measurement cannot be skipped—identical glands with different trapping need very different administered activities.

The absorbed-dose (Marinelli–Quimby style) approach

A fuller method targets an absorbed dose $D$ (in gray) to the thyroid. The mean absorbed dose from a beta-dominant internal emitter is proportional to the time-integrated activity concentration in the gland:

D \propto \frac{A \cdot f \cdot T _{eff}}{m}

so, rearranging for the administered activity needed to reach a target dose:

A \propto \frac{D \cdot m}{f \cdot T _{eff}}

This is the structure of the classic Quimby–Marinelli formulation used for thyroid dosimetry: the administered activity scales with the target dose and gland mass, and inversely with uptake and effective half-life. The proportionality constant embeds the beta energy per decay and unit conversions and must be taken from a validated dosimetry reference for the units used.³⁸ The practical caution is that the simplified formula can under- or over-estimate the delivered dose if it ignores the dose deposited during the first 24 hours or assumes a standard effective half-life that does not match the patient—published analyses show the resulting error can be clinically meaningful.⁸

Target doses. Absorbed-dose targets depend on intent. Non-ablative strategies aim lower; ablative strategies for Graves disease often target higher. Individualized-dosimetry series report high single-administration cure rates when the delivered thyroid dose reaches roughly 200–300 Gy, while historical cohort reconstructions estimate mean thyroid doses near 120–140 Gy from the administered activities actually used.⁴⁷ The authorized user sets the target for each patient.

Clinical Impact

The dosimetry decision directly shapes the two outcomes patients care about: cure of hyperthyroidism and the likelihood of subsequent hypothyroidism. These two goals pull in opposite directions—more dose cures more reliably but drives more hypothyroidism—so the "right" activity depends on the clinical strategy chosen with the patient.⁵

Modeling shows cure follows an increasing (roughly logarithmic) relationship to absorbed dose while hypothyroidism rises more linearly, which is why many programs now openly favor ablative dosing and plan for thyroid hormone replacement rather than chasing an elusive euthyroid endpoint.⁵ Toxic multinodular goiter and toxic adenomas generally require higher activity than diffuse Graves disease because autonomous nodular tissue is more radioresistant and uptake is more heterogeneous.¹²

Accurate inputs matter clinically. Overestimating gland mass or using an outdated uptake value propagates directly into a mis-dose. Because the calculation depends on a trustworthy uptake measurement, the quality of the uptake system and its calibration and of the dose-measuring instruments is part of the therapy's clinical reliability, not a separate technical footnote.

Practical Optimization Tips

1. Measure gland mass properly

Use ultrasound (or a validated scintigraphic estimate) rather than palpation alone for calculated dosing. Mass enters every calculated formula linearly, so a 25% mass error is a 25% activity error.

2. Use a current, correctly performed 24-hour uptake

Confirm the patient has followed low-iodine and medication-hold instructions (recent iodinated contrast or antithyroid drugs distort uptake), and measure uptake on a calibrated system with an appropriate neck phantom and background correction.

3. Match the target to the clinical goal

Decide explicitly with the authorized user whether the intent is non-ablative control or ablation, and set the target concentration or absorbed dose accordingly—do not default to a habitual activity for every patient.²⁵

4. Document the calculation

Record mass, uptake, target, formula, and resulting activity in the patient record and the written directive. This supports the medical-physics QA, the authorized user's decision, and regulatory review.

5. Verify the administered activity

Measure the actual dispensed activity in a calibrated dose calibrator before administration and reconcile it against the written directive; a discrepancy beyond the directive can become a reportable medical event.

Common pitfalls to avoid

Skipping the uptake correction. Identical glands with different uptake need very different activities.
Palpation-only mass estimates. They are unreliable and propagate directly into the dose.
Assuming a standard effective half-life for everyone. It varies and can bias absorbed-dose calculations.⁶⁸
Treating toxic nodular disease like Graves. Nodular tissue generally needs more activity.¹²
Under-documenting. The written directive and the calculation record are both a safety tool and a regulatory requirement.

Regulatory Considerations

Medical use of I-131 in the United States is regulated under NRC 10 CFR Part 35 (or the equivalent Agreement State program), and radioiodine therapy touches several specific requirements. The states DRPS serves are mostly NRC Agreement States (Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, New Jersey), while Washington DC and Delaware are regulated directly by the NRC; confirm which authority licenses your facility.¹⁰

Written directive (10 CFR 35.40). A written directive signed and dated by the authorized user is required before administering any sodium iodide I-131 dosage greater than 1.11 MBq (30 µCi). It must specify the radionuclide, dosage, and route.¹⁰
Authorized-user training (10 CFR 35.392). Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 GBq (33 mCi) falls under §35.392—this range encompasses typical hyperthyroidism activities. Larger activities (thyroid cancer) fall under §35.394.¹⁰
Patient release (10 CFR 35.75) and NRC Regulatory Guide 8.39. A patient may be released if the total effective dose equivalent to any other individual is not likely to exceed 5 mSv (0.5 rem). The release calculation and written radiation-safety instructions to the patient (and specific instructions if the patient is breastfeeding) are documented.¹⁰¹¹
Medical-event reporting (10 CFR 35.3045). Administrations that fall outside the written directive by the regulatory thresholds are reportable, reinforcing the need to verify dispensed activity.¹⁰

For the downstream radiation-safety side of therapy, see caregiver and family dose after radiopharmaceutical therapy. DRPS aligns these requirements with practical workflows through radiation safety officer consulting and medical physicist consulting; requirements vary by authority, so confirm with the authority having jurisdiction.

Frequently Asked Questions (FAQs)

What is I-131 therapy for hyperthyroidism?

Radioiodine therapy uses orally administered sodium iodide I-131, which the thyroid concentrates and which delivers a therapeutic radiation dose to overactive thyroid tissue almost entirely through short-range beta particles. It is a definitive treatment for Graves disease, toxic multinodular goiter, and toxic autonomous nodules, with the goal of rendering the patient euthyroid or, more often, controlled hypothyroid on replacement therapy.

Should the activity be fixed or calculated?

Both approaches are in accepted clinical use. A fixed-activity approach administers a standard activity (for example, roughly 370–555 MBq / 10–15 mCi for Graves disease). A calculated approach adjusts activity for gland mass and 24-hour radioiodine uptake, and sometimes for effective half-life. Calculated dosing can achieve comparable or better outcomes with lower average administered activity, but it requires accurate mass and uptake measurements. Guidelines support individualized selection based on the clinical goal.

How is the calculated activity determined?

The most common practical method targets a radioiodine concentration in the gland (microcuries or megabecquerels per gram) and corrects for uptake: administered activity equals (target concentration × gland mass) divided by the fractional 24-hour uptake. A fuller dosimetric method targets an absorbed dose to the thyroid (in gray) and additionally accounts for the effective half-life of iodine in the gland.

What thyroid absorbed dose is targeted?

Targets vary with intent. Non-ablative strategies may aim near the lower end, while ablative strategies for Graves disease often target higher doses. Published individualized-dosimetry work reports high cure rates when the delivered thyroid absorbed dose reaches roughly the 200–300 Gy range, and historical cohort reconstructions estimate mean thyroid doses of about 120–140 Gy from typical administered activities. The specific target should be set by the authorized user for the individual patient.

Why does the 24-hour uptake matter so much?

Only the fraction of administered iodine that the gland actually traps and retains contributes to the therapeutic dose. A gland with high uptake needs less administered activity to reach a target dose; a gland with low uptake needs more. Skipping the uptake correction systematically mis-doses patients, so a measured 24-hour radioiodine uptake is central to calculated dosing.

What are the main radiation-safety and regulatory requirements?

In the United States, medical use of I-131 falls under NRC (or Agreement State) 10 CFR Part 35. A written directive is required before administering any sodium iodide I-131 dosage greater than 1.11 MBq (30 µCi). The authorized user must meet the training requirements for oral I-131 (10 CFR 35.392 covers dosages up to 1.22 GBq / 33 mCi, which encompasses typical hyperthyroidism activities). Patient release is governed by 10 CFR 35.75 and NRC Regulatory Guide 8.39, based on the 5 mSv dose limit to other individuals, with written instructions provided to the patient.

Can hyperthyroidism patients be treated as outpatients?

Usually yes. Typical hyperthyroidism activities are well within the range where patients can be released under 10 CFR 35.75 provided the calculated dose to any other individual is not likely to exceed 5 mSv and the patient receives written radiation-safety instructions. The medical physicist and authorized user document the release calculation and instructions; individual circumstances (home environment, caregivers, public transport) can affect the decision.

Key Takeaways

The dose is delivered by beta particles. I-131's short-range betas do the therapeutic work; the 364 keV gamma is why patient-release and shielding matter.⁹
Three inputs drive every method: gland mass, 24-hour uptake, and effective half-life.⁶
Fixed and calculated dosing are both legitimate. Calculated (uptake-corrected) dosing can lower average activity; a well-chosen fixed activity remains defensible.⁵⁶
The uptake correction is non-negotiable for calculated dosing. Identical glands with different uptake require very different activities.
Target follows intent. Ablative goals target higher thyroid doses (roughly 200–300 Gy in individualized series) than non-ablative strategies.⁷
Regulation wraps the calculation. Written directive above 30 µCi, §35.392 training, and 10 CFR 35.75 / Reg Guide 8.39 patient release govern the therapy.¹⁰¹¹

Conclusion

Radioiodine therapy for hyperthyroidism is simple to administer and complex to optimize. The administered activity is not an arbitrary number of millicuries; it is the output of a biokinetic calculation—gland mass, 24-hour uptake, effective half-life—matched to a clinical target and constrained by the NRC written-directive and patient-release framework. Whether a program uses fixed or calculated dosing, understanding the physics behind the number lets the medical physicist and authorized user defend the choice, document it, and deliver a treatment that is both effective and safe.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and radioiodine therapy programs build defensible, well-documented dosing and radiation-safety workflows. This can include uptake-system and dose-calibrator calibration support, review of fixed and calculated dosing protocols, written-directive and patient-release procedure development, radiation-safety instruction templates, and authorized-user and staff training aligned with NRC and Agreement State requirements—through PET/CT and nuclear medicine physics, radiation safety officer consulting, and medical physicist consulting.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware, with work performed by board-certified medical physicists.

Related Resources

References

Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. Journal of Nuclear Medicine. 2012;53(10):1633-1651. doi:10.2967/jnumed.112.105148. doi.org
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229. doi.org
Stokkel MPM, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(11):2218-2228. doi:10.1007/s00259-010-1536-8. doi.org
Melo DR, Brill AB, Zanzonico P, et al. Organ Dose Estimates for Hyperthyroid Patients Treated with 131I: An Update of the Thyrotoxicosis Follow-Up Study. Radiation Research. 2015;184(6):595-610. doi:10.1667/RR14160.1. doi.org
Doi SAR, Loutfi I, Al-Shoumer KAS. A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism. BMC Nuclear Medicine. 2001;1(1):1. doi:10.1186/1471-2385-1-1. doi.org
Peña Pardo FJ, López Serrano R, García Cases FJ, et al. A prospective comparative study of two methods of individual calculation of 131I activity in the treatment of hyperthyroidism. Endocrinología, Diabetes y Nutrición. 2020;67(9):568-577. doi:10.1016/j.endinu.2020.02.009. doi.org
Schiavo M, Bagnara MC, Calamia I, et al. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid. Journal of Endocrinological Investigation. 2010;34(3):201-205. doi:10.1007/BF03347067. doi.org
Chen Y, Huang J, Wang Y, Xie S, He F. Errors in the absorbed and the administered 131I therapeutic dose in patients with Graves' disease. A suggested more precise technique. Hellenic Journal of Nuclear Medicine. 2017;20(3):217-221. doi:10.1967/s002449910602. doi.org
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material (§§ 35.40, 35.75, 35.392, 35.3045). nrc.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of Patients Administered Radioactive Material. nrc.gov